0001209191-13-045762.txt : 20130926 0001209191-13-045762.hdr.sgml : 20130926 20130926161609 ACCESSION NUMBER: 0001209191-13-045762 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130924 FILED AS OF DATE: 20130926 DATE AS OF CHANGE: 20130926 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CELGENE CORP /DE/ CENTRAL INDEX KEY: 0000816284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 131116991 BUSINESS ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 BUSINESS PHONE: (908)673-9000 MAIL ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2013-09-24 0 0001280600 ACCELERON PHARMA INC XLRN 0000816284 CELGENE CORP /DE/ 86 MORRIS AVENUE SUMMIT NJ 07901 0 0 1 0 Common Stock 2013-09-24 4 C 0 457875 A 457875 D Common Stock 2013-09-24 4 J 0 57899 A 515774 D Common Stock 2013-09-24 4 C 0 1990446 A 2506220 D Common Stock 2013-09-24 4 P 0 666667 15.00 A 3172887 D Series C-1 Convertible Preferred Stock 2013-09-24 4 C 0 457875 0.00 D Common Stock 457875 0 D Series E Convertible Preferred Stock 2013-09-24 4 J 0 36496 0.00 D Common Stock 57899 0 D Series F Convertible Preferred Stock 2013-09-24 4 C 0 1990446 0.00 D Common Stock 1990446 0 D Upon closing of the Issuer's initial public offering, each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Common Stock without payment of further consideration. The shares had no expiration date. Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock automatically converted at a ratio of 1-for-1.58645 into the number of shares of Common Stock shown in column 7 without payment of further consideration. The shares had no expiration date. Upon closing of the Issuer's initial public offering, each share of Series F Preferred Stock automatically converted into one share of Common Stock without payment of further consideration. The shares had no expiration date. Chairman of the Board of Directors, Chief Executive Officer and President /s/Robert J Hugin_______________________ Robert J Hugin, Attorney-in-Fact 2013-09-26